Q-omics provides the consensus-scored ANXA3 profile across patient tissues and cancer cell-line models. ANXA3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ANXA3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ANXA3 protein abundance shows 25,049 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where ANXA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANXA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANXA3 survival associations across molecular data types. ANXA3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANXA3 RNA expression–survival associations across cancer types. High ANXA3 expression shows unfavorable associations in HNSC, PAAD and CESC, but favorable associations in COAD, LIHC and KICH. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify HNSC as the clearest survival context for ANXA3 RNA expression.
This table summarizes ANXA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ANXA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANXA3 shows lower tumor expression in KIRC, KICH, LUAD, LUSC and BRCA and higher tumor expression in COAD. The KIRC box plot shows higher ANXA3 RNA expression in normal versus tumor tissue (log2 FC = −2.677, t-test p < 0.001).
This table shows molecular features associated with ANXA3 in patient tissues and cancer cell lines. In patient samples, ANXA3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANXA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and OESOPHAGUS.
